Clinical Trial Update: IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IK-1001 (sodium sulfide for injection) in patients with ST-segment elevation myocardial infarction has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• St-segment Elevation Myocardial Infarction

Drugs mentioned

• IK-1001 (Sodium sulfide for injection)

Snippet

Sponsor: Mallinckrodt | Conditions: ST-Segment Elevation Myocardial Infraction | Phase 2 | Status: WITHDRAWN